Abstract
The widespread introduction of tyrosine kinase inhibitor (TKI) therapy has radically changed the treatment strategy and goals of treatment of chronic myeloid leukemia (CML). In the past, allogeneic transplantation offered the only alternative for “curative” therapy, and the use of this modality was limited by patient age and donor availability. In a mere decade of use, TKI therapy has pushed transplantation to a salvage therapy, and most chronic-phase patients can expect prolonged response, with a small risk of progression to advanced-phase disease. Indeed, we now can speak of a “functional cure” and can now even consider discontinuing therapy for those patients without molecular evidence of disease. Given the multiple tyrosine kinase inhibitors now available to clinicians, as well as sensitive and relatively noninvasive methods to monitor disease response, we are now at the enviable phase of being able to optimize response based on the individual treatment goals of the patient and physician.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.